Stephanie Olsen
Cardiovascular Disease · Farmington, UTNPI 1396730404
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 66 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Boston Scientific at 40.1% of the total. Reporting peaked in 2019 at $418 and has fallen 94.8% since, to $22 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in UT, where the typical reported total is $1,352.
Across 66 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$491
- Medtronic$197
- Novartis$116
- Actelion Pharmaceuticals US, Inc.$111
- Abbott$102
- Teleflex LLC$44
- plus $162 from 9 others
Across 22 payments — averaging $18,393 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$399K
- Novartis$6K
What the payments were for
- Food & beverage$1,16295%
- Education$615%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 24 | $491 |
| Medtronic(2 entities) | 12 | $197 |
| Novartis | 6 | $116 |
| Actelion Pharmaceuticals US, Inc. | 8 | $111 |
| Abbott | 3 | $102 |
| Teleflex LLC | 3 | $44 |
| Lantheus Medical Imaging, Inc. | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 2 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Johnson & Johnson | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Irhythm Technologies, Inc. | 1 | $14 |
| AstraZeneca | 1 | $13 |
| Bayer | 1 | $12 |
How this compares
$1,224 in reported general payments places this provider in the 45th percentile of 131 cardiovascular disease providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 40 | $57,576 |
| Repatha SureclickEvolocumab | 14 | $15,110 |
| SotalolSotalol Hcl | 18 | $1,525 |
| Rosuvastatin Calcium | 107 | $1,338 |
| Flecainide Acetate | 24 | $1,219 |
| Niacin ErNiacin | 15 | $984 |
| Olmesartan Medoxomil | 42 | $799 |
| Nebivolol Hcl | 21 | $794 |
| Carvedilol | 83 | $793 |
| ClopidogrelClopidogrel Bisulfate | 80 | $719 |
| Irbesartan | 18 | $698 |
| Atorvastatin Calcium | 71 | $632 |
| Metoprolol Succinate | 35 | $627 |
| Amlodipine Besylate | 64 | $514 |
| Losartan Potassium | 43 | $504 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Farmington
- Christopher KimFarmington$36K
- Daniel FronkFarmington$13K
- John RyanSalt Lake City$1.4M
- Robert FowlesSalt Lake City$611K
- Brian WhisenantMurray$416K
- Andrew BehuninDraper$192K
- Jeffrey OsbornSalt Lake City$69K
- James FangSalt Lake City$67K
- Joseph MuhlesteinMurray$65K
- Hannah RaaschSalt Lake City$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.